ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Cipla profit rises on strong growth in India, US businesses

US generics business keeps market share in key assets

Employees and security staff work at the reception area of Cipla at its headquarters in Mumbai, India   © Reuters

MUMBAI (NewsRise) -- Indian drug maker Cipla reported a 5.7% rise in third quarter profit on the back of robust growth at home as well as the U.S.

The Indian drug maker has been growing its business amid strong domestic demand as well as supplying to global public health programs. The company's relatively limited exposure to the U.S. generic drug market at about 22% of overall revenue has been helping it sidestep intense price competition in the largest drug market in the world.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more